About Coherus BioSciences (NASDAQ:CHRS)
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530
Debt
Debt-to-Equity Ratio3.33%
Current Ratio5.12%
Quick Ratio5.12%
Price-To-Earnings
Trailing P/E Ratio-2.66
Forward P/E Ratio-3.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.56 million
Price / Sales458.84
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book23.33
Profitability
EPS (Most Recent Fiscal Year)($4.48)
Net Income$-238,170,000.00
Net MarginsN/A
Return on Equity-493.03%
Return on Assets-126.67%
Miscellaneous
Employees122
Outstanding Shares60,150,000
Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions
What is Coherus BioSciences' stock symbol?
Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus BioSciences' earnings last quarter?
Coherus BioSciences (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.02. View Coherus BioSciences' Earnings History.
When is Coherus BioSciences' next earnings date?
What price target have analysts set for CHRS?
8 equities research analysts have issued 12-month target prices for Coherus BioSciences' stock. Their forecasts range from $15.00 to $46.00. On average, they expect Coherus BioSciences' stock price to reach $31.6250 in the next year. View Analyst Ratings for Coherus BioSciences.
What are Wall Street analysts saying about Coherus BioSciences stock?
Here are some recent quotes from research analysts about Coherus BioSciences stock:
- 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (1/9/2018)
- 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)
Who are some of Coherus BioSciences' key competitors?
Some companies that are related to Coherus BioSciences include Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Fate Therapeutics (FATE), EntreMed (CASI), Voyager Therapeutics (VYGR), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX) and PDL Biopharma (PDLI).
Who are Coherus BioSciences' key executives?
Coherus BioSciences' management team includes the folowing people:
- Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 63)
- Dr. Jean-Frédéric Viret, CFO & Principal Accounting Officer (Age 52)
- Dr. Peter K. Watler Ph.D., Chief Technical Officer (Age 56)
- Dr. Alan C. Herman, Chief Scientific Officer (Age 70)
- Dr. Barbara K. Finck M.D., Chief Medical Officer (Age 71)
Has Coherus BioSciences been receiving favorable news coverage?
News stories about CHRS stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Coherus BioSciences earned a news impact score of 0.15 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Coherus BioSciences?
Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus BioSciences' stock price today?
One share of CHRS stock can currently be purchased for approximately $11.90.
How big of a company is Coherus BioSciences?
Coherus BioSciences has a market capitalization of $724.86 million and generates $1.56 million in revenue each year. The biotechnology company earns $-238,170,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Coherus BioSciences employs 122 workers across the globe.
How can I contact Coherus BioSciences?
Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]
MarketBeat Community Rating for Coherus BioSciences (CHRS)
MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Coherus BioSciences (NASDAQ:CHRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Coherus BioSciences in the last 12 months. Their average twelve-month price target is $31.6250, suggesting that the stock has a possible upside of 165.76%. The high price target for CHRS is $46.00 and the low price target for CHRS is $15.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $31.6250 | $31.6250 | $32.00 | $34.00 |
| Price Target Upside: | 165.76% upside | 166.88% upside | 161.22% upside | 164.59% upside |
Coherus BioSciences (NASDAQ:CHRS) Consensus Price Target History
Coherus BioSciences (NASDAQ:CHRS) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Coherus BioSciences (NASDAQ:CHRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Coherus BioSciences (NASDAQ CHRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 26.28%
Institutional Ownership Percentage: 82.29%
Coherus BioSciences (NASDAQ CHRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/8/2017 | Alan C Herman | Insider | Sell | 17,535 | $15.02 | $263,375.70 | 49,651 |  |
| 7/5/2017 | Alan C Herman | Insider | Sell | 600 | $15.00 | $9,000.00 | 67,186 | |
| 4/3/2017 | Alan C Herman | Insider | Sell | 11,333 | $20.73 | $234,933.09 | 90,452 | |
| 1/25/2017 | Jean-Frederic Viret | CFO | Sell | 3,900 | $27.00 | $105,300.00 | 6,892 | |
| 12/16/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $28.30 | $110,370.00 | 6,225 | |
| 12/8/2016 | Mats Wahlstrom | Director | Sell | 53,583 | $27.52 | $1,474,604.16 | | |
| 12/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $27.40 | $310,524.20 | 143,917 | |
| 10/21/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $30.62 | $119,418.00 | 6,225 | |
| 10/3/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.69 | $291,144.77 | 161,687 | |
| 9/26/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $29.88 | $116,532.00 | 6,225 | |
| 9/21/2016 | Dennis M Lanfear | Insider | Sell | 4,060 | $31.75 | $128,905.00 | 71,635 | |
| 9/16/2016 | Dennis M Lanfear | Insider | Sell | 2,900 | $31.79 | $92,191.00 | 71,635 | |
| 8/8/2016 | Fmr Llc | Insider | Sell | 100,000 | $29.86 | $2,986,000.00 | | |
| 8/5/2016 | Fmr Llc | Insider | Sell | 48,600 | $28.48 | $1,384,128.00 | | |
| 8/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.54 | $289,444.82 | 186,782 | |
| 7/21/2016 | Peter K Watler | Insider | Sell | 3,991 | $26.13 | $104,284.83 | 3,991 | |
| 7/20/2016 | Peter K Watler | Insider | Sell | 73,741 | $25.02 | $1,844,999.82 | 50,000 | |
| 7/11/2016 | Peter K Watler | Insider | Sell | 43,495 | $20.02 | $870,769.90 | | |
| 7/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $16.89 | $71,782.50 | 198,115 | |
| 6/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $18.67 | $79,347.50 | 202,365 | |
| 5/17/2016 | Peter K Watler | Insider | Sell | 12,000 | $20.00 | $240,000.00 | | |
| 5/2/2016 | Alan C Herman | Insider | Sell | 4,250 | $19.20 | $81,600.00 | 207,167 | |
| 2/5/2016 | Alan C Herman | Insider | Sell | 2,000 | $15.02 | $30,040.00 | 221,615 | |
| 12/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $29.49 | $334,210.17 | 211,865 | |
| 11/13/2015 | Christos Richards | Director | Sell | 15,000 | $27.49 | $412,350.00 | 63,836 | |
| 11/2/2015 | Alan C. Herman | insider | Sell | 18,416 | $28.71 | $528,723.36 | 214,699 | |
| 10/1/2015 | Alan C. Herman | insider | Sell | 4,250 | $18.98 | $80,665.00 | 214,699 | |
| 9/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $27.39 | $310,410.87 | 214,699 | |
| 8/18/2015 | Mats Wahlstrom | Director | Sell | 6,373 | $33.50 | $213,495.50 | | |
| 8/17/2015 | Mats Wahlstrom | Director | Sell | 8,028 | $33.91 | $272,229.48 | | |
| 8/14/2015 | Mats Wahlstrom | Director | Sell | 116,554 | $34.24 | $3,990,808.96 | | |
| 6/15/2015 | August J Troendle | Director | Sell | 250,000 | $26.68 | $6,670,000.00 | | |
| 11/12/2014 | Eli & Co Lilly | Insider | Buy | 164,963 | $13.50 | $2,227,000.50 | | |
(Data available from 1/1/2013 forward)
Coherus BioSciences (NASDAQ CHRS) News Headlines
| Source: |
|
Coherus BioSciences (NASDAQ:CHRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Coherus BioSciences (NASDAQ:CHRS) Income Statement, Balance Sheet and Cash Flow Statement
Coherus BioSciences (NASDAQ CHRS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
